6594 Journal of Medicinal Chemistry, 2007, Vol. 50, No. 26
Mugnaini et al.
(6) Kati, W. M.; Johnson, K. A.; Jerva, L. F.; Anderson, K. S. Mechanism
and Fidelity of HIV Reverse Transcriptase. J. Biol. Chem. 1992, 267,
25988–25997.
(26) Goodsell, D. S.; Morris, G. M.; Olson, A. J. Automated Docking of
Flexible Ligands: Applications of AutoDock. J. Mol. Recognit. 1996,
9, 1–5.
(7) Menéndez-Arias, L.; Matamoros, T.; Deval, J.; Canard, B. Molecular
Mechanism of Resistance to Nucleoside Analogue Inhibitors of Human
Immunodeficiency Virus Reverse Transcriptase. Drug Des. ReV. 2005,
2, 101–113.
(8) Ren, J.; Esnouf, R.; Garman, E.; Somers, D.; Ross, C.; Kirby, I.;
Keeling, J.; Darby, G.; Jones, Y.; Stuart, D.; Stammers, D. High-
Resolution Structures oh HIV-1 RT from Four RT-Inhibitor Com-
plexes. Nat. Struct. Biol. 1995, 2, 293–302.
(9) Smerdon, S. J.; Jager, J.; Wang, J.; Kohlstaedt, L. A.; Chirino, A. J.;
Friedman, J. M.; Rice, P. A.; Stetz, T. A. Structure of the binding site
of Nonnucleoside Inhibitors of the Reverse Transcriptase of Human
Immunodeficiency Virus Type 1. Proc. Natl. Acad. Sci. U.S.A. 1994,
91, 3911–3915.
(10) De Clercq, E. Non-Nucleoside Reverse Transcriptase Inhibitors
(NNRTIs): Past, Present, and Future. Chem. BiodiVersity 2004, 1, 44–
64.
(27) Hsiou, Y.; Das, K.; Ding, J.; Clark, A. D., Jr.; Kleim, J.-P.; Rösner,
M.; Winkler, I.; Günter, R.; Hughes, S. H.; Arnold, E. Structures of
Tyr188Leu mutant and wild-type HIV-1 reverse transcriptase com-
plexed with the non-nucleoside inhibitor HBY 097: inhibitor flexibility
is a useful design feature for reducing drug resistance. J. Mol. Biol.
1998, 284, 313–323.
(28) Ren, J.; Nichols, C.; Bird, L.; Chamberlain, P.; Weaver, K.; Short,
S.; Stuart, D. I.; Stammers, D. K. Structural mechanisms of drug
resistance for mutations at codons 181 and 188 in HIV-1 reverse
transcriptase and the improved resilience of second generation non-
nucleoside inhibitors. J. Mol. Biol. 2001, 312, 795–805.
(29) Lindberg, J.; Sigurdsson, S.; Lowgren, S.; Andersson, H. O.; Sahlberg,
C.; Noreen, R.; Fridborg, K.; Zhang, H.; Unge, T. Structural basis for
the inhibitory efficacy of efavirenz (DMP-266), MSC194 and
PNU142721 towards the HIV-1 RT K103N mutant. Eur. J. Biochem.
2002, 269, 1670–1677.
(11) Das, K.; Lewi, P. J.; Hughes, S. H.; Arnold, E. Crystallography and
the Design of anti-AIDS Drugs: Conformational Flexibility and
Positional Adaptability are Important in the Design of Non-nucleoside
HIV-1 Reverse Transcriptase Inhibitors. Prog. Biophys. Mol. Biol.
2005, 88, 209–231.
(12) Ren, J.; Stammers, D. K. HIV Reverse Transcriptase Structures:
Designing New Inhibitors and Understanding Mechanisms of Drug
Resistance. Trends Pharmacol. Sci. 2005, 26, 4–7.
(13) Sarafianos, S. G.; Das, K.; Hughes, S. H.; Arnold, E. Taking Aim at
Moving Target: Designing Drugs to Inhibit Drug Resistant HIV-1
Reverse Transcriptases. Curr. Opin. Struct. Biol 2004, 14, 716–730.
(14) Basavapathruni, A.; Anderson, K. S. Developing Novel Nucleoside
HIV-1 Reverse Transcriptase Inhibitors: Beyond the Butterfly. Curr.
Pharm. Des 2006, 12, 1857–1865.
(30) Rodriguez-Barrios, F.; Balzarini, J.; Gago, F. The molecular basis of
resilience to the effect of the Lys103Asn mutation in non-nucleoside
HIV-1 reverse transcriptase inhibitors studied by targeted molecular
dynamics simulations. J. Am. Chem. Soc. 2005, 127, 7570–7578.
(31) Shen, L.; Shen, J.; Luo, X.; Xu, Y.; Chen, X.; Arnold, E.; Ding, J.;
Jiang, H. Steered molecular dynamics simulation on the binding of
NNRTI to HIV-1 RT. Biophys. J. 2003, 84, 3547–3563.
(32) Mai, A.; Sbardella, G.; Artico, M.; Ragno, R.; Massa, S.; Novellino,
E.; Greco, G.; Lavecchia, A.; Musiu, C.; La Colla, M.; Murgioni, C.;
La Colla, P.; Loddo, R. Structure-based design, synthesis, and
biological evaluation of conformationally restricted novel 2-alkylthio-
6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-
ones as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
J. Med. Chem. 2001, 44, 2544–2554.
(15) Sluis-Cremer, N.; Temiz, N. A.; Bahar, I. Conformational Changes
in HIV-1 Reverse Transcriptase Induced by Nonnucleoside Reverse
Transcriptase Inhibitor Binding. Curr. HIV Res. 2004, 2, 323–332.
(16) Das, K.; Clark, A. D.; Lewi, P. J.; Heeres, J.; de Jonge, M. R.;
Koymans, L. M. H.; Vinkers, K. M.; Daeyaert, F.; Ludovici, D. W.;
Kukla, M. J.; De Corte, B.; Kavash, R. W.; Ho, C. Y.; Ye, H.;
Lichtenstein, M. A.; Andries, K.; Pauwels, R.; de Béthune, M.-P.;
Boyer, P. L.; Clark, P.; Hughes, S. H.; Jansenn, P. A. J.; Arnold, E.
Roles of Conformational and Positional Adaptability in Structure-Based
Design of TMC125-R165335 (Etravirine) and Related Non-Nucleoside
Reverse Transcriptase Inhibitors that are Highly Potent and Effective
against Wild-Type and Drug-Resistant HIV-1 Variants. J. Med. Chem.
2004, 47, 2550–2560.
(17) Botta, M.; Artico, M.; Massa, S.; Gambacorta, A.; Marongiu, M. E.;
Pani, A.; La Colla, P. Synthesis, Antimicrobial and Antiviral Activities
of Isotrimethoprim and Some Related Derivatives. Eur. J. Med. Chem.
1992, 27, 251–257.
(18) Mai, A.; Artico, M.; Ragno, R.; Sbardella, G.; Massa, S.; Musiu, C.;
Mura, M.; Marturana, F.; Cadeddu, A.; Maga, G.; La Colla, P. 5-Alkyl-
2-alkylamino-6-(2,6-difluorophenylalkyl)-3,4-dihydropyrimidin-4(3H)-
ones, a New Series of Potent, Broad-Spectrum Non-Nucleoside
Reverse Transcriptase Inhibitors Belonging to the DABO Family.
Bioorg. Med. Chem. 2005, 13, 2065–2077.
(19) Ragno, R.; Mai, A.; Sbardella, G.; Artico, M.; Massa, S.; Musiu, C.;
Mura, M.; Marturana, F.; Cadeddu, A.; La Colla, P. Computer-Aided
Design, Synthesis, and Anti-HIV-1 Activity in Vitro of 2-Alkylamino-
6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-
ones as Novel Potent Non-Nucleoside Reverse Transcriptase Inhibitors,
Also Active Against the Y181C Variant. J. Med. Chem. 2004, 47,
928–934.
(20) Mugnaini, C.; Manetti, F.; Este, J. A.; Clotet-Codina, I.; Maga, G.;
Cancio, R.; Botta, M.; Corelli, F. Synthesis and Biological Investigation
of S-Aryl-S-DABO Derivatives as HIV-1 Inhibitors. Bioorg. Med.
Chem. Lett. 2006, 16, 3541–3544.
(33) Jaeger, R.; Robinson, R. Two Ketones of the Stilboestrol Group.
J. Chem. Soc. 1941, 131, 744–747.
(34) Mai, A.; Artico, M.; Sbardella, G.; Massa, S.; Novellino, E.; Greco,
G.; Loi, A. G.; Tramontano, E.; Marongiu, M. E.; La Colla, P. 5-Alkyl-
2-(alkylthio)-6-(2,6-dihalophenylmethyl)-3,4-dihydropyrimidin-4(3H)-
ones: Novel potent and selective dihydro-alkoxy-benzyl-oxopyrimidine
derivatives. J. Med. Chem. 1999, 42, 619–627.
(35) Sbardella, G.; Mai, A.; Artico, M.; Massa, S.; Marceddu, T.; Vargiu,
L.; Marongiu, M. E.; La Colla, P. Does the 2-methylthiomethyl
substituent really confer high anti-HIV-1 activity to S-DABOs. Med.
Chem. Res. 2000, 10, 30–39.
(36) Mohamadi, F.; Richards, N. G. J.; Guida, W. C.; Liskamp, R.; Lipton,
M.; Caufield, C.; Chang, G.; Hendrickson, T.; Still, W. C. Macro-
model-an integrated software system for modeling organic and
bioorganic molecules using molecular mechanics. J. Comput. Chem.
1990, 11, 440–467.
(37) Maestro, version 7.5; Schro¨dinger: New York, 2006.
(38) Jorgensen, W. L.; Maxwell, D. S.; Tirado-Rives, J. Development and
testing of the OPLS all-atom force field on conformational energetics
and properties of organic liquids. J. Am Chem. Soc. 1996, 118, 11225–
11236.
(39) Schmidt, M. W.; Baldridge, K. K.; Boatz, J. A.; Elbert, S. T.; Gordon,
M. S.; Jensen, J. H.; Koseki, S.; Matsunaga, N.; Nguyen, K. A.; Su,
S.; Windus, T. L.; Dupuis, M.; Montgomery, J. A. General atomic
and molecular electronic structure system. J. Comput. Chem. 1993,
14, 1347–1363.
(40) Singh, U. C.; Kollman, P. A. An approach to computing electrostatic
charges for molecules. J. Comput. Chem. 1984, 5, 129–145.
(41) Cornell, W. D.; Cieplak, P.; Bayly, C. I.; Gould, I. R.; Merz, K. M.,
Jr.; Ferguson, D. M.; Spellmeyer, D. C.; Fox, T.; Caldwell, J. W.;
Kollman, P. A. A second generation force field for the simulation of
proteins, nucleic acids, and organic molecules. J. Am. Chem. Soc. 1995,
117, 5179–51977.
(21) Manetti, F.; Este, J. A.; Clotet-Codina, I.; Armand-Ugon, M.; Maga,
G.; Crespan, E.; Cancio, R.; Mugnaini, C.; Bernardini, C.; Togninelli,
A.; Carmi, C.; Alongi, M.; Petricci, E.; Massa, S.; Corelli, F.; Botta,
M. Parallel Solution-Phase and Microwave-Assisted Synthesis of New
S-DABO Derivatives Endowed with Subnanomolar Anti-HIV-1 Activ-
ity. J. Med. Chem. 2005, 48, 8000–8008.
(22) Togninelli, A.; Carmi, C.; Petricci, E.; Mugnaini, C.; Massa, S.; Corelli,
F.; Botta, M. Solution-Phase Parallel Synthesis of S-DABO Analogues.
Tetrahedron Lett. 2006, 47, 65–67.
(23) Clay, R. J.; Collom, T. A.; Karrick, G. L.; Wemple, J. A. Safe,
Economical Method for the Preparation of ꢀ-Oxo Esters. Synthesis
1993, 290, 292.
(24) Cerius, version 4.10; Accelrys Software, Inc.: San Diego, CA.
(25) Kier, L. B.; Hall, L. H. Molecular ConnectiVity in Chemistry and Drug
Research. Academic Press Inc., New York, 1976; p 257.
(42) Phillips, J. C.; Braun, R.; Wang, W.; Gumbart, J.; Tajkhorshid, E.;
Villa, E.; Chipot, C.; Skeel, R. D.; Kale, L.; Schulten, K. Scalable
molecular dynamics with NAMD. J. Comput. Chem. 2005, 26, 1781–
1802.
(43) Humphrey, W.; Dalke, A.; Schulten, K. VMD: Visual molecular
dynamics. J. Mol. Graphics 1996, 14, 33–38.
(44) Jorgensen, W. L.; Chandrasekhar, J.; Madura, J. D.; Impey, R. W.;
Klein, M. L. Comparison of simple potential functions for simulating
liquid water. J. Chem. Phys. 1983, 79, 926–935.
(45) Essman, U.; Perera, L.; Berkowitz, M. L.; Darden, T.; Lee, H.;
Pedersen, L. A smooth particle mesh Ewald method. J. Chem. Phys.
1995, 103 (19), 8577–8593.
(46) Tuckerman, M.; Berne, B.; Martyna, G. Reversible multiple time scale
molecular dynamics. J. Chem. Phys. 1992, 97, 1990–2001.